Home
News
Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive r/r AML

Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive r/r AML

27 giugno 2023 - Newsletter n. 35 - Giugno 2023

Attenzione! Il presente contenuto è disponibile solo in lingua originale.

Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 ((NMS-088), a novel, potent FLT3 inhibitor) in positive Relapsed or Refractory Acute Myeloid Leukemia.

full article

Tags: NMS-03592088 r/r AML

Come giudichi questo contenuto?

Utile Non utile

Grazie per il tuo feedback!

Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive r/r AML

Come giudichi questo contenuto?

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Intercept announced receipt of a Complete Response Letter (CRL) from FDA for its Ocaliva

AstraZeneca and Daiichi Sankyo announced the voluntary withdrawal of the US application of Dato-DXd (TROP2 ADC) for 2L+ locally advanced or metastatic non-squamous (Nsq) lung cancer (NSCLC)